BMS partners with Gritstone on solid tumor combos; Roche's Alzheimer's diagnostic gets breakthrough status
→ Bristol-Myers Squibb $BMY is teaming up with Emeryville, CA-based Gritstone Oncology to try out a cancer combo against solid tumors. The companies are trying BMS’ Opdivo and Yervoy with Gritsone’s personalized neoantigen treatment. They’re starting out testing the Opdivo combo in common solid tumors like metastatic non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. They’ll also test Gritstone’s drug with systemic Opdivo and a localized injection of Yervoy. Gritsone’s president and CEO Andrew Allen said this in a statement: “The emergence of immunotherapies in the last decade has transformed the way we think about treating cancer, yet there remains a need for new therapies, which can initiate immune system recognition of tumors. We have developed our programs using insights from our proprietary tumor antigen discovery platform, EDGE, together with an immunotherapy platform which has demonstrated the ability to elicit an enhanced antigen-directed T-cell response in preclinical primate models.”
→ Roche has nabbed a breakthrough device designation for Elecsys, its in vitro diagnostic that detects Alzheimer’s disease by measuring amyloid beta and phospho-tau concentrations in cerebrospinal fluid, putting the device on a fast track at the FDA.